Alendronic acid

Drug Profile

Alendronic acid

Alternative Names: Adronat; AHButBP; Alend; Alendronate; Alendronate disodium; Alendronate sodium hydrate; Alendros; Bonalon; Bonalon Jelly; Dronal; Fosalan; Fosamax; G 704650; GTH 42; GTH-42J; GTH-42V; GTH-42W; L 670452; Marvil; MK 217; Onclast; Osteosan®; Sodium alendronate trihydrate; Teiroc

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Gador; Istituto Gentili
  • Developer Teijin Pharma
  • Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bone disorders; Osteogenesis imperfecta
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Corticosteroid-induced osteoporosis; Fracture; Male osteoporosis; Malignant hypercalcaemia; Osteitis deformans; Osteoporosis; Postmenopausal osteoporosis
  • No development reported Bone resorption

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 05 Feb 2014 MSD Korea and Hanmi Pharmaceutical agree to co-promote alendronic acid in South Korea for prevention of osteoporosis
  • 15 Aug 2012 Registered for Osteoporosis in Japan (PO, Jelly, 35mg, once-weekly)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top